Literature DB >> 24916269

TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord.

Johannes Brettschneider1, Kimihito Arai, Kelly Del Tredici, Jon B Toledo, John L Robinson, Edward B Lee, Satoshi Kuwabara, Kazumoto Shibuya, David J Irwin, Lubin Fang, Vivianna M Van Deerlin, Lauren Elman, Leo McCluskey, Albert C Ludolph, Virginia M-Y Lee, Heiko Braak, John Q Trojanowski.   

Abstract

We examined the phosphorylated 43-kDa TAR DNA-binding protein (pTDP-43) inclusions as well as neuronal loss in full-length spinal cords and five selected regions of the central nervous system from 36 patients with amyotrophic lateral sclerosis (ALS) and 10 age-matched normal controls. The most severe neuronal loss and pTDP-43 lesions were seen in lamina IX motor nuclei columns 4, 6, and 8 of lower cervical segments and in columns 9-11 of lumbosacral segments. Severity of pTDP-43 pathology and neuronal loss correlated closely with gray and white matter oligodendroglial involvement and was linked to onset of disease, with severe involvement of columns 4, 6, and 8 of upper extremity onset cases and severe involvement of columns of 9, 10, and 11 in cases with lower extremity onset. Severe TDP-43 lesions and neuronal loss were observed in stage 4 cases and sometimes included Onuf's nucleus. Notably, three cases displayed pTDP-43 aggregates in the midbrain oculomotor nucleus, which we had not seen previously even in cases with advanced (i.e., stage 4) pathology. pTDP-43 aggregates were observed in neurons of Clarke's column in 30.6 % of cases but rarely in the intermediolateral nucleus (IML). Gray matter oligodendroglial pTDP-43 inclusions were present in areas devoid of neuronal pTDP-43 aggregates and neuronal loss. Taken together, our findings indicate that (1) the dorsolateral motor nuclei columns of the cervical and lumbosacral anterior horn may be the earliest foci of pTDP-43 pathology in the spinal cord, (2) gray matter oligodendroglial involvement is an early event in the ALS disease process that possibly heralds subsequent involvement of neurons by pTDP-43 pathology, and (3) in some very advanced cases, there is oculomotor nucleus involvement, which may constitute an additional neuropathological stage (designated here as stage 5) of pTDP-43 pathology in ALS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24916269      PMCID: PMC4384652          DOI: 10.1007/s00401-014-1299-6

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  63 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

Review 3.  Defining the NG2-expressing cell of the adult CNS.

Authors:  Philip J Horner; Michaela Thallmair; Fred H Gage
Journal:  J Neurocytol       Date:  2002 Jul-Aug

Review 4.  Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration.

Authors:  Edward B Lee; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2011-11-30       Impact factor: 34.870

5.  Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis.

Authors:  Johannes Brettschneider; David J Libon; Jon B Toledo; Sharon X Xie; Leo McCluskey; Lauren Elman; Felix Geser; Virginia M Y Lee; Murray Grossman; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2012-01-01       Impact factor: 17.088

6.  Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p.

Authors:  Heather Stewart; Nicola J Rutherford; Hannah Briemberg; Charles Krieger; Neil Cashman; Marife Fabros; Matt Baker; Alice Fok; Mariely DeJesus-Hernandez; Andrew Eisen; Rosa Rademakers; Ian R A Mackenzie
Journal:  Acta Neuropathol       Date:  2012-01-07       Impact factor: 17.088

7.  Building an integrated neurodegenerative disease database at an academic health center.

Authors:  Sharon X Xie; Young Baek; Murray Grossman; Steven E Arnold; Jason Karlawish; Andrew Siderowf; Howard Hurtig; Lauren Elman; Leo McCluskey; Vivianna Van Deerlin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2011-07       Impact factor: 21.566

8.  Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases.

Authors:  Wouter van Rheenen; Marka van Blitterswijk; Mark H B Huisman; Lotte Vlam; Perry T C van Doormaal; Meinie Seelen; Jelena Medic; Dennis Dooijes; Marianne de Visser; Anneke J van der Kooi; Joost Raaphorst; Helenius J Schelhaas; W Ludo van der Pol; Jan H Veldink; Leonard H van den Berg
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

9.  Phases of A beta-deposition in the human brain and its relevance for the development of AD.

Authors:  Dietmar R Thal; Udo Rüb; Mario Orantes; Heiko Braak
Journal:  Neurology       Date:  2002-06-25       Impact factor: 9.910

10.  Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72.

Authors:  Johnathan Cooper-Knock; Christopher Hewitt; J Robin Highley; Alice Brockington; Antonio Milano; Somai Man; Joanne Martindale; Judith Hartley; Theresa Walsh; Catherine Gelsthorpe; Lynne Baxter; Gillian Forster; Melanie Fox; Joanna Bury; Kin Mok; Christopher J McDermott; Bryan J Traynor; Janine Kirby; Stephen B Wharton; Paul G Ince; John Hardy; Pamela J Shaw
Journal:  Brain       Date:  2012-03       Impact factor: 13.501

View more
  94 in total

1.  Cdc48/VCP and Endocytosis Regulate TDP-43 and FUS Toxicity and Turnover.

Authors:  Guangbo Liu; Aaron Byrd; Amanda N Warner; Fen Pei; Eman Basha; Allison Buchanan; J Ross Buchan
Journal:  Mol Cell Biol       Date:  2020-01-30       Impact factor: 4.272

Review 2.  Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies.

Authors:  Lin Guo; James Shorter
Journal:  Cold Spring Harb Perspect Med       Date:  2017-09-01       Impact factor: 6.915

3.  An Assessment of Possible Neuropathology and Clinical Relationships in 46 Sporadic Amyotrophic Lateral Sclerosis Patient Autopsies.

Authors:  Grant Coan; Cassie S Mitchell
Journal:  Neurodegener Dis       Date:  2015-07-16       Impact factor: 2.977

Review 4.  Biological Spectrum of Amyotrophic Lateral Sclerosis Prions.

Authors:  Magdalini Polymenidou; Don W Cleveland
Journal:  Cold Spring Harb Perspect Med       Date:  2017-11-01       Impact factor: 6.915

5.  Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis.

Authors:  Sebum Lee; Yulei Shang; Stephanie A Redmond; Anatoly Urisman; Amy A Tang; Kathy H Li; Alma L Burlingame; Ryan A Pak; Ana Jovičić; Aaron D Gitler; Jinhua Wang; Nathanael S Gray; William W Seeley; Teepu Siddique; Eileen H Bigio; Virginia M-Y Lee; John Q Trojanowski; Jonah R Chan; Eric J Huang
Journal:  Neuron       Date:  2016-06-16       Impact factor: 17.173

Review 6.  Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks.

Authors:  Stefanie M A Willekens; Donatienne Van Weehaeghe; Philip Van Damme; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-08       Impact factor: 9.236

Review 7.  Mechanisms of TDP-43 Proteinopathy Onset and Propagation.

Authors:  Han-Jou Chen; Jacqueline C Mitchell
Journal:  Int J Mol Sci       Date:  2021-06-02       Impact factor: 5.923

8.  Missing in Action: Dysfunctional RNA Metabolism in Oligodendroglial Cells as a Contributor to Neurodegenerative Diseases?

Authors:  Peter Hoch-Kraft; Jacqueline Trotter; Constantin Gonsior
Journal:  Neurochem Res       Date:  2019-03-06       Impact factor: 3.996

9.  White matter structural network abnormalities underlie executive dysfunction in amyotrophic lateral sclerosis.

Authors:  Dennis Dimond; Abdullah Ishaque; Sneha Chenji; Dennell Mah; Zhang Chen; Peter Seres; Christian Beaulieu; Sanjay Kalra
Journal:  Hum Brain Mapp       Date:  2016-10-31       Impact factor: 5.038

10.  Exosome secretion is a key pathway for clearance of pathological TDP-43.

Authors:  Yohei Iguchi; Lara Eid; Martin Parent; Geneviève Soucy; Christine Bareil; Yuichi Riku; Kaori Kawai; Shinnosuke Takagi; Mari Yoshida; Masahisa Katsuno; Gen Sobue; Jean-Pierre Julien
Journal:  Brain       Date:  2016-09-27       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.